WO1985000816A1 - Procede de fabrication d'oligonucleotides - Google Patents

Procede de fabrication d'oligonucleotides Download PDF

Info

Publication number
WO1985000816A1
WO1985000816A1 PCT/EP1984/000244 EP8400244W WO8500816A1 WO 1985000816 A1 WO1985000816 A1 WO 1985000816A1 EP 8400244 W EP8400244 W EP 8400244W WO 8500816 A1 WO8500816 A1 WO 8500816A1
Authority
WO
WIPO (PCT)
Prior art keywords
groups
group
nucleoside
general formula
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1984/000244
Other languages
German (de)
English (en)
French (fr)
Inventor
Hubert KÖSTER
Nanda Dual Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE8484903173T priority Critical patent/DE3474964D1/de
Priority to AT84903173T priority patent/ATE38386T1/de
Publication of WO1985000816A1 publication Critical patent/WO1985000816A1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to a process for the preparation of oligonucleotides of the general formula I specified in claim 1.
  • the oligonucleotides produced according to the invention have defined sequences and can be used as specific primers and probes or are of great importance for the synthesis of complete genes (drug research 30, 3a, 548, (1980)).
  • oligonucleotides are produced either by the phosphate or phosphite triester method using polymeric carriers (Nachr. Chem. Tech. Lab. 2 9, 230 (1981)).
  • the individual building blocks (nucleosides or nucleotides) must be provided with suitable protective groups.
  • base-labile acyl groups are generally used to protect the exocyclic amino groups of the heterocyclic nucleobases
  • a base-labile ester bond is usually used to anchor the oligonucleotide chain to the polymeric support
  • the acid-labile trityl ether groups are used to protect the primary 5'-OH group.
  • Either the 2-chlorophenyl or 4-chlorophenyl group in an ester-like bond is usually used as the phosphate protective group of the phosphate triester method, which can only be removed by attacking a base or a nucleophile on the phosphorus atom. In itself, such a step is undesirable because it does there is a risk of cleavage of the internucleotide phosphate ester bond. This danger was greatly reduced by the use of oximate anions (Tetrahedron Lett.
  • the methyl group in ester-like bond is usually used as the phosphate protective group, which can be removed by attacking a nucleophile on the methyl carbon atom (J. Amer. Chem. Soc. 99, 3526 (1977)). Since an attack on the P atom is avoided, the risk of cleavage of the internucleotide bond is also avoided.
  • Thiophenol / triethylamine is usually used as the nucleophile, which is uncomfortable to handle and also leads to non-volatile, difficult to extract compounds which, as mentioned above, both complicate the work-up and lead to considerable material losses.
  • B is a nucleobase, for example adenine (A), guanine (G), cytosine (C), thymine (T) or uracil (U) or their analogs and R 1 is hydrogen, hydroxyl or hydroxyl protected with protective groups customary in nucleotide chemistry and n is an integer from 1 to 200, various defined reaction steps are to be carried out according to the invention:
  • R of the general formula II can be hydrogen; the compounds of the formula I are then oligodeoxynucleotides.
  • the group R 1 can also be hydroxyl or optionally hydroxyl protected with protective groups customary in nucleotide chemistry.
  • Protecting groups of this type are, for example, trityl, monomethoxytrityl and dimethoxytrityl, acyl, for example acetyl, benzoyl; Tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl and silyl ethers such as t-butyl-diphenylsilyl ether.
  • R 2 is also common in nucleotide chemistry
  • Protecting group according to the aforementioned publications preferably the acid-labile 4,4-dirrethoxy or 4,4,4-trimethoxytrityl group.
  • B 'can also have a protective group customary in' nucleotide chemistry according to the above-mentioned prior publications.
  • the nucleoside of the formula II is reacted according to the invention with a phosphine derivative of the general formula III according to claim 1.
  • X means chlorine, bromine, CN or
  • SCN means chlorine, bromine, CN, SCN or an amine radical of the formula (Formula VIII), wherein the groups R 4 are primary, secondary or tertiary alkyl radicals with 1-10 carbon atoms or together form a cycloalkyl radical with 5-7 carbon atoms, optionally with alkyl branches, and / or one or two nitrogen, oxygen and / or May contain sulfur atoms as heteroatoms.
  • the group L can also form a reactive heterocyclic radical, the imidazolyl, triazolyl, tetrazolyl, 3-nitro-1,2,4-triazolyl, thiazolyl, pyrrolyl, benzotriazolyl (optionally with substituents in the phenyl radical) or benzhydroxytriazolyl (optionally with substituents in the phenyl ring ) and the like.
  • R 3 of the phosphine derivative of the general formula (III) is a group of the general formula VII which can be removed by means of bases by ⁇ -elimination and in which Y is hydrogen, methyl or ethyl.
  • Z represents an electron-withdrawing group, for example halogen such as fluorine, chlorine or bromine, CN, NO 2 .
  • Z can furthermore mean phenyl, phenylthio, phenylsulfoxy or phenylsulfonyl, it being possible for the phenyl radicals to be substituted in the o, o'-position and / or p-position by halogen, CN or NO 2 .
  • the group VII which can be removed by means of bases by ⁇ -elimination and in which Y is hydrogen, methyl or ethyl.
  • Z represents an electron-withdrawing group, for example halogen such as fluorine, chlorine or bromine, CN, NO 2 .
  • Z
  • CF 3 can also be one of the groups CF 3 , CCl 3 or CBr 3 .
  • step a takes place in the presence of an organic base.
  • step b reaction of the nucleosidephosphoric acid derivative of the formula IV obtained in step a.
  • the reaction of the compound according to formula IV takes place with a nucleoside of the general formula V according to claim 1 bound to a polymeric support.
  • Soluble or insoluble, i.e. cross-linked polymeric supports are used, e.g. modified silica gel, glass, in particular "controlled poreglass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like.
  • ester bonds are preferred, including those which are derived from levulinyl or ⁇ -benzoylpropionyl radical; the latter ester bonds can be cleaved with hydrazine under neutral conditions.
  • the acid-labile trityl ether bond optionally with substituents in the phenyl rings, can also be considered as anchoring option, cf. Liebigs Ann. Chem. 1974, 959.
  • the oxidation leads to a phosphate group; it can be carried out, for example, with iodine / H 2 O, H 2 O 2 or organic peracids or generally by oxidation by introducing O, S or Se.
  • the cleavage takes place, for example, using a protonic acid or Lewis acid such as ZnBr 2 or dialkylaluminum chloride if R 2 represents a trityl group or methoxy derivative thereof.
  • a protonic acid or Lewis acid such as ZnBr 2 or dialkylaluminum chloride if R 2 represents a trityl group or methoxy derivative thereof.
  • Steps a - e can be repeated, with at least one nucleoside phosphate residue being introduced.
  • chain extensions of more than one nucleoside phosphate unit are of course achieved.
  • This cleavage can be carried out in such a way that, with aqueous ammonia, the N-acyl groups of the heterocyclic bases, the ester bond between oligonucleotide and support (if appropriate the latter can also be cleaved with hydrazine under neutral conditions) and the phosphate protective group according to the general scheme 1 be split off at the end of the description by ß-elimination.
  • An oligonucleotide with only 5 '-terminal trityl protecting group is then obtained, which can be purified in a manner known per se after the volatile base (ammonia) has been removed by high pressure liquid chromatography (HPLC) on "reversed phase" material.
  • the intermediates of the general formula IV according to claim 1 are new compounds. They are in the form of very stable compounds which can be prepared in pure form, are easy to handle and nevertheless quite reactive in terms of the formation of internucleotide bonds.
  • the use of R 3 as one by bases over ß-elimination Removable protective group makes it possible for the first time to cleave all protective groups apart from the 5'-trityl group, the desired oligonucleotide advantageously being contaminated to a very small extent with foreign substances by use of volatile bases and thus immediately subsequently by the hydrophobic 5 still present '-Trityl group can be purified via "reversed phase" HPLC.
  • Another advantage of the method of the invention results from the fact that the removal of the protective group by ⁇ -elimination does not result in an attack on the P atom and therefore cannot be cleaved at any of the newly formed internucleotide bonds during deprotection.
  • the method of the invention thus leads to overall purer products than the previously available methods with a greatly reduced expenditure of time.
  • Figures 1a, 1b and 1c show 31 P-NMR spectra of three different monochloro-ß-cyanoethyl phosphoramidites.
  • the N-morpholine derivative is thermally too unstable to be distilled.
  • the preparation is nevertheless so pure that the residue can be used directly for the production of the activated nucleoside derivatives.
  • the purity is usually greater than 95% according to the 31 p NMR spectra.
  • Complete deprotection and cleavage from the carrier is achieved in one step by reacting the glass beads with concentrated aqueous ammonia (3 ml) at 50 ° C. in 16 hours. The glass beads are then washed thoroughly with 50% aqueous methanol (3 times with 3 ml each). The liquid phase is removed by concentration (removal of the methanol) and freeze-drying. An aliquot is then cleaned after filtration through Millipore filters by HPLC on RP 18, as can be seen from FIG. 3. The fractions containing the 5'-dimethoxytritylated oligonucleotide are collected; the volatile buffer is removed in vacuo on a rotary evaporator. The residue is mixed with 1 ml of 80% acetic acid. The acetic acid is removed after 45 minutes at room temperature by freeze drying.
  • the material thus obtained is usually phosphorylated with T4 polynucleotide kinase and ⁇ - 32 P-ATP (Liebigs Ann. Chem. 1978, 982).
  • the product obtained is compared to a homo-oligodT wavelength standard (Nucleic Acids Res. 6, 2096 (1979) by polyacrylamide gel electrophoresis.
  • Figures 6a to 6c show the results (HPLC, gel electrophoresis, sequencing) of the synthesis of d (GGGATCCC) using the nucleoside-ß-cyanoethyl-N, N-dimethylphosphophamidite.
  • Figures 7a to 7c show the results (HPLC, gel electrophoresis, sequencing the synthesis of d (GGGATATCCC) using the

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
PCT/EP1984/000244 1983-08-18 1984-08-10 Procede de fabrication d'oligonucleotides Ceased WO1985000816A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE8484903173T DE3474964D1 (en) 1983-08-18 1984-08-10 Process for producing oligonucleotides
AT84903173T ATE38386T1 (de) 1983-08-18 1984-08-10 Verfahren zur herstellung von oligonucleotiden.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833329892 DE3329892A1 (de) 1983-08-18 1983-08-18 Verfahren zur herstellung von oligonucleotiden
DEP3329892.0 1983-08-18

Publications (1)

Publication Number Publication Date
WO1985000816A1 true WO1985000816A1 (fr) 1985-02-28

Family

ID=6206891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1984/000244 Ceased WO1985000816A1 (fr) 1983-08-18 1984-08-10 Procede de fabrication d'oligonucleotides

Country Status (9)

Country Link
US (1) US4725677A (enExample)
EP (1) EP0152459B1 (enExample)
JP (2) JPS60502102A (enExample)
AT (1) ATE38386T1 (enExample)
AU (1) AU3313784A (enExample)
CA (1) CA1234060A (enExample)
DE (2) DE3329892A1 (enExample)
IT (1) IT1198910B (enExample)
WO (1) WO1985000816A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216357A3 (en) * 1985-09-25 1988-08-31 Nippon Zeon Co., Ltd. Phosphoramidite compounds and process for production thereof
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US9034798B2 (en) 2003-01-16 2015-05-19 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Families Citing this family (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973679A (en) * 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US5166330A (en) * 1983-09-06 1992-11-24 Hoechst Aktiengesellschaft Process for the preparation of nucleoside alkyl-aralkyl- and aryl-phosphonites and -phosphonates
EP0222889B1 (en) * 1985-05-15 1993-10-27 Amoco Corporation Cytidine analogs
JPH0680071B2 (ja) 1985-10-07 1994-10-12 日本ゼオン株式会社 ホスホルアミダイト化合物及びその製造法
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
EP0260032B1 (en) * 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
WO1988003149A1 (fr) * 1986-10-30 1988-05-05 Daicel Chemical Industries, Ltd. Procede de synthese d'oligonucleotides et composes servant a former des groupes protecteurs a poids moleculaire eleve
US4835104A (en) * 1987-06-16 1989-05-30 Ajinomoto Co., Inc., Patent & Licensing Department Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides
US6306647B1 (en) 1987-06-16 2001-10-23 Ajinomoto Co., Inc. Process for producing and purifying 2′,3′-dideoxynucleosides, and process for producing 2′,3′-dideoxy-2′,3′-didehydronucleosides
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US6031091A (en) * 1987-09-21 2000-02-29 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
WO1989009221A1 (en) * 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
WO1989009780A1 (en) * 1988-04-15 1989-10-19 Chemical Industry Institute Of Toxicology Site-specific tritium-labeled oligodeoxynucleotides
US5602244A (en) * 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5750666A (en) * 1988-05-26 1998-05-12 Competitve Technologies, Inc. Polynucleotide phosphorodithioate compounds
JP3028814B2 (ja) * 1988-06-28 2000-04-04 ベイラー カレッジ オブ メディシン 生体高分子の分割合成のための多孔質ウエハー
JPH0291088A (ja) * 1988-09-29 1990-03-30 Central Glass Co Ltd ホスファイトおよびヌクレオシド‐３’‐ホスファイト誘導体およびこれを用いるオリゴヌクレオチドの合成法
CA2000805C (en) * 1988-10-17 1994-01-18 Kiyoshi Sudani Carbon/metal composite
US5262530A (en) * 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) * 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
DE3916871A1 (de) * 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5646265A (en) * 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0592434T3 (da) * 1990-10-26 1999-06-21 Genta Inc Forbedret fremgangsmåde til syntese af oligomerer
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
CA2122365C (en) * 1991-11-26 2010-05-11 Brian Froehler Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
ZA929351B (en) * 1991-12-11 1993-06-04 Igen Inc Electrochemiluminescent label for DNA assays.
WO1993012135A1 (en) 1991-12-12 1993-06-24 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5795714A (en) * 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
US6436635B1 (en) * 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US6194144B1 (en) 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
CA2165821C (en) * 1993-06-23 2002-01-08 Albert D. Friesen Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
US5571902A (en) * 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5614621A (en) * 1993-07-29 1997-03-25 Isis Pharmaceuticals, Inc. Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
US6294664B1 (en) 1993-07-29 2001-09-25 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US6558633B1 (en) 1994-09-21 2003-05-06 Isis Pharmaceuticals, Inc. Chemical reaction apparatus and methods
USRE43097E1 (en) 1994-10-13 2012-01-10 Illumina, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US6428955B1 (en) 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US20060063193A1 (en) * 1995-04-11 2006-03-23 Dong-Jing Fu Solid phase sequencing of double-stranded nucleic acids
US7803529B1 (en) 1995-04-11 2010-09-28 Sequenom, Inc. Solid phase sequencing of biopolymers
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
DE69638179D1 (de) 1995-06-07 2010-06-10 Solexa Inc Verfahren zur Verbesserung der Effizienz der Polynukleotidsequenzierung
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6146854A (en) * 1995-08-31 2000-11-14 Sequenom, Inc. Filtration processes, kits and devices for isolating plasmids
JP2000500740A (ja) * 1995-10-19 2000-01-25 プロリゴ・エルエルシー オリゴヌクレオチドの溶液相合成方法
US6160109A (en) * 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US5734041A (en) * 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US5705621A (en) * 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
US5808035A (en) * 1995-12-08 1998-09-15 Usher; David A. Protected nucleoside and method for its synthesis
EP0932698A1 (en) * 1996-03-26 1999-08-04 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US6024925A (en) 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
US6133436A (en) 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US6140053A (en) * 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
DE69727489T2 (de) 1996-11-06 2004-11-25 Sequenom, Inc., San Diego Verfahren zur massenspektrometrie
CA2270132A1 (en) * 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
US7285422B1 (en) * 1997-01-23 2007-10-23 Sequenom, Inc. Systems and methods for preparing and analyzing low volume analyte array elements
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6172217B1 (en) 1996-12-27 2001-01-09 Isis Pharmaceuticals Inc. Method of synthesizing phosphorothioate oligonucleotides
US5902881A (en) 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
US7427678B2 (en) * 1998-01-08 2008-09-23 Sigma-Aldrich Co. Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US6020475A (en) * 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US7875440B2 (en) 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6780591B2 (en) * 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
US6274725B1 (en) 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6919437B1 (en) 1998-06-11 2005-07-19 Isis Pharmaceuticals, Inc. Synthetic methods and intermediates for triester oligonucleotides
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6124484A (en) 1998-07-17 2000-09-26 Isis Pharmaceuticals, Inc. Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US6673912B1 (en) 1998-08-07 2004-01-06 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US20040009938A1 (en) * 1998-08-07 2004-01-15 Muthiah Manoharan Methods of enhancing renal uptake of oligonucleotides
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
US6069243A (en) * 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6153411A (en) 1998-10-30 2000-11-28 American Water Works Company, Inc. Methods and kits for detection of Cryptosporidium parvum using immunomagnetic separation and amplification
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6264891B1 (en) * 1998-12-22 2001-07-24 Eos Biotechnology, Inc. Apparatus and method for concurrent chemical synthesis
US6380378B1 (en) 1998-12-24 2002-04-30 Toagosei Company, Ltd. Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
US6465628B1 (en) * 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6225061B1 (en) 1999-03-10 2001-05-01 Sequenom, Inc. Systems and methods for performing reactions in an unsealed environment
US20040082774A1 (en) * 1999-03-16 2004-04-29 Guzaev Andrei P. Novel phosphate and thiophosphate protecting groups
US6121437A (en) * 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6399765B1 (en) 1999-03-17 2002-06-04 Isis Pharmaceuticals, Inc. Methods for removing dimethoxytrityl groups from oligonucleotides
CA2370478A1 (en) 1999-03-24 2000-09-28 Serge L. Beaucage N-acylphosphoramidites and their use in oligonucleotide synthesis
US6221635B1 (en) 1999-05-06 2001-04-24 The Wistar Institute Methods for solid-phase amplification of DNA template (SPADT) using multiarrays
US6610842B1 (en) 1999-05-06 2003-08-26 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomers using phosphoramidite compositions
US20070059752A1 (en) * 1999-06-09 2007-03-15 Biosearch Technologies, Inc. Fluorescence energy transfer probes with stabilized conformations
US7501245B2 (en) * 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US6818395B1 (en) * 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6114518A (en) * 1999-09-30 2000-09-05 Becton, Dickinson And Company Synthesis and use of labelled phosphoramidite compositions
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US6936702B2 (en) * 2000-06-07 2005-08-30 Li-Cor, Inc. Charge-switch nucleotides
JP2004516810A (ja) 2000-06-07 2004-06-10 リ−コール インコーポレーティッド 電荷スイッチヌクレオチド
US7135565B2 (en) * 2000-07-28 2006-11-14 Agilent Technologies, Inc. Synthesis of polynucleotides using combined oxidation/deprotection chemistry
DK1349958T3 (da) 2000-09-26 2009-09-21 Boston Probes Inc Prober, probesæt, fremgangsmåder og kits til at opnå påvisning, identifikation og/eller tælling af bakterier
US6693187B1 (en) * 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
WO2002055199A2 (en) 2000-10-30 2002-07-18 Sequenom Inc Method and apparatus for delivery of submicroliter volumes onto a substrate
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
CA2440754A1 (en) * 2001-03-12 2002-09-19 Stephen Quake Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US6825338B2 (en) 2001-03-30 2004-11-30 Isis Pharmaceuticals, Inc. Labeled oligonucleotides, methods for making same, and compounds useful therefor
JP2005505749A (ja) 2001-05-21 2005-02-24 アクララ バイオサイエンシーズ， インコーポレイテッド タンパク質を分析するための方法および組成物
US7118907B2 (en) * 2001-06-06 2006-10-10 Li-Cor, Inc. Single molecule detection systems and methods
AU2002322351A1 (en) * 2001-06-28 2003-03-03 Ia, Inc. Fiber-optic sensor array
CA2652991A1 (en) * 2001-07-16 2003-11-13 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
US7355037B2 (en) * 2001-12-03 2008-04-08 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile hydroxyl protecting groups and methods of use
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
GB0200526D0 (en) * 2002-01-11 2002-02-27 Science And Technology The Methods
US7098326B2 (en) * 2002-01-23 2006-08-29 Sigma-Aldrich Co. Methods for the integrated synthesis and purification of oligonucleotides
KR20040088520A (ko) * 2002-02-22 2004-10-16 허니웰 인터내셔널 인코포레이티드 포스피틸레이티드 화합물 제조방법
WO2003077851A2 (en) * 2002-03-11 2003-09-25 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
CA2477670A1 (en) * 2002-03-15 2003-09-25 Arcturus Bioscience, Inc. Improved nucleic acid amplification
US7169916B2 (en) * 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
CA2482863A1 (en) 2002-04-17 2003-10-30 Roberto Crea Universal libraries for immunoglobulins
AU2003249681A1 (en) * 2002-05-31 2003-12-19 Diversa Corporation Multiplexed systems for nucleic acid sequencing
US6967247B2 (en) 2002-07-24 2005-11-22 Isis Pharmaceuticals, Inc. Deprotection of phosphorus in oligonucleotide synthesis
AU2003273298B2 (en) * 2002-09-08 2008-03-06 Applera Corporation Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1560840B1 (en) * 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7615629B2 (en) * 2002-12-31 2009-11-10 Sigma-Aldrich Co. Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support
US7002006B2 (en) * 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US7745116B2 (en) * 2003-04-08 2010-06-29 Pacific Biosciences Of California, Inc. Composition and method for nucleic acid sequencing
US7276599B2 (en) * 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
US20050170367A1 (en) * 2003-06-10 2005-08-04 Quake Stephen R. Fluorescently labeled nucleoside triphosphates and analogs thereof for sequencing nucleic acids
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
US7125945B2 (en) * 2003-09-19 2006-10-24 Varian, Inc. Functionalized polymer for oligonucleotide purification
US7169560B2 (en) * 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
DK2708541T3 (en) 2003-11-13 2015-02-23 Isis Pharmaceuticals Inc 5,6-dihydroxy-isoindole derivatives as linkers for oligomeric solid phase synthesis
WO2005054441A2 (en) * 2003-12-01 2005-06-16 California Institute Of Technology Device for immobilizing chemical and biomedical species and methods of using same
US7691316B2 (en) * 2004-02-12 2010-04-06 Chemistry & Technology For Genes, Inc. Devices and methods for the synthesis of nucleic acids
DE602005020421D1 (de) 2004-02-19 2010-05-20 Helicos Biosciences Corp Verfahren zur analyse von polynukleotidsequenzen
US20060046258A1 (en) * 2004-02-27 2006-03-02 Lapidus Stanley N Applications of single molecule sequencing
JP4814084B2 (ja) * 2004-03-05 2011-11-09 株式会社キラルジェン ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005085272A1 (ja) * 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US20050239085A1 (en) * 2004-04-23 2005-10-27 Buzby Philip R Methods for nucleic acid sequence determination
US20050260609A1 (en) * 2004-05-24 2005-11-24 Lapidus Stanley N Methods and devices for sequencing nucleic acids
US20070117104A1 (en) * 2005-11-22 2007-05-24 Buzby Philip R Nucleotide analogs
DE602005027700D1 (de) * 2004-05-25 2011-06-09 Helicos Biosciences Corp Verfahren zur nukleinsäureimmobilisierung
US20070117103A1 (en) * 2005-11-22 2007-05-24 Buzby Philip R Nucleotide analogs
US7476734B2 (en) * 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
CA2568735A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20060024678A1 (en) * 2004-07-28 2006-02-02 Helicos Biosciences Corporation Use of single-stranded nucleic acid binding proteins in sequencing
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP2008517950A (ja) * 2004-10-25 2008-05-29 オペロン ホールディングス， インコーポレイテッド アミノ官能基化またはチオール官能基化された核酸の合成のためのアミノリンカーまたはチオールリンカーの構築ブロック、並びにこれらを作製および使用する方法
DE602004032245D1 (de) 2004-11-16 2011-05-26 Qiagen Gmbh Genabschaltung (Gene silencing) durch hybride Sens-DNA und Antisens-RNA Konstrukte, gekoppelt an ein Peptid zur erleichterten Aufnahme in Zellen
US20060118754A1 (en) * 2004-12-08 2006-06-08 Lapen Daniel C Stabilizing a polyelectrolyte multilayer
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US7220549B2 (en) * 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US20060172328A1 (en) * 2005-01-05 2006-08-03 Buzby Philip R Methods and compositions for correcting misincorporation in a nucleic acid synthesis reaction
US7482120B2 (en) * 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7608433B2 (en) 2005-02-09 2009-10-27 Idexx Laboratories Method of detection of classical swine fever
US20060263790A1 (en) * 2005-05-20 2006-11-23 Timothy Harris Methods for improving fidelity in a nucleic acid synthesis reaction
EP1907855A4 (en) * 2005-07-12 2009-11-11 Univ Temple GENETIC AND EPIGENETIC CHANGES IN THE DIAGNOSIS AND TREATMENT OF CANCER
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US20070117102A1 (en) * 2005-11-22 2007-05-24 Buzby Philip R Nucleotide analogs
US20070128610A1 (en) * 2005-12-02 2007-06-07 Buzby Philip R Sample preparation method and apparatus for nucleic acid sequencing
US7579459B2 (en) * 2005-12-12 2009-08-25 Ngo Nam Q Activator bound solid supports for nucleic acid synthesis via the phosphoramidite approach
US20090305248A1 (en) * 2005-12-15 2009-12-10 Lander Eric G Methods for increasing accuracy of nucleic acid sequencing
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
ES2516815T3 (es) 2006-01-27 2014-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
US7397546B2 (en) * 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
US20080309926A1 (en) * 2006-03-08 2008-12-18 Aaron Weber Systems and methods for reducing detected intensity non uniformity in a laser beam
US8362234B2 (en) * 2006-03-24 2013-01-29 Archemix Llc Solid support reagents for synthesis
WO2007136989A2 (en) * 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of dgat2
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2008027558A2 (en) 2006-08-31 2008-03-06 Codon Devices, Inc. Iterative nucleic acid assembly using activation of vector-encoded traits
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) * 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2188298B1 (en) * 2007-08-15 2013-09-18 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2009039122A2 (en) 2007-09-17 2009-03-26 Sequenom, Inc. Integrated robotic sample transfer device
US8546556B2 (en) * 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
EP2980217A1 (en) 2007-12-31 2016-02-03 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
US8530640B2 (en) * 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009117589A1 (en) 2008-03-21 2009-09-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
EP2285819B1 (en) * 2008-04-04 2013-10-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8636978B2 (en) * 2008-06-23 2014-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclized NGR peptide compounds, compositions, and methods of their use
EP2346883B1 (en) 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010036696A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
WO2010036698A1 (en) * 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
CN104212799B (zh) 2008-10-15 2018-11-23 Ionis制药公司 因子11表达的调节
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010048585A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
US8715927B2 (en) * 2008-12-02 2014-05-06 Oregon Health & Science University Inhibition of DNA polymerases to augment chemotherapeutic and antimicrobial agents
RU2011134857A (ru) 2009-01-21 2013-02-27 Вертекс Фармасьютикалз Инкорпорейтед Способы амплификации нуклеиновых кислот вируса гепатита с
US8536320B2 (en) 2009-02-06 2013-09-17 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
EP2669290A1 (en) 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
US7960526B2 (en) * 2009-03-30 2011-06-14 Berry And Associates, Inc. Colorimetric-oxycarbonyl protecting groups for use in organic syntheses
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
WO2011005861A1 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011056872A2 (en) 2009-11-03 2011-05-12 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
WO2011066185A1 (en) 2009-11-25 2011-06-03 Gen9, Inc. Microfluidic devices and methods for gene synthesis
EP3085791A1 (en) 2009-11-25 2016-10-26 Gen9, Inc. Methods and apparatuses for chip-based dna error reduction
US9217144B2 (en) 2010-01-07 2015-12-22 Gen9, Inc. Assembly of high fidelity polynucleotides
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
US8716467B2 (en) 2010-03-03 2014-05-06 Gen9, Inc. Methods and devices for nucleic acid synthesis
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
EP2558586B1 (en) 2010-04-12 2016-10-12 Somalogic, Inc. APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
AU2011338841B2 (en) 2010-11-12 2017-02-16 Gen9, Inc. Methods and devices for nucleic acids synthesis
EP2637780B1 (en) 2010-11-12 2022-02-09 Gen9, Inc. Protein arrays and methods of using and making the same
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
PH12013501373B1 (en) 2010-12-27 2019-05-10 Elanco Us Inc Bovine viral diarrhea virus type 1b vaccine compositions and methods
EP3375878A1 (en) 2010-12-30 2018-09-19 Dow AgroSciences LLC Nucleic acid molecules that target the vacuolar atphase h subunit and confer resistance to coleopteran pests
CN103403162A (zh) 2010-12-30 2013-11-20 陶氏益农公司 赋予对鞘翅目有害生物的抗性的核酸分子
UY33852A (es) 2010-12-30 2012-07-31 Dow Agrosciences Llc ?moléculas de ácido nucleico que se dirigen a la proteína de unión a gtp pequeña de rho1 y que confieren resistencia a las plagas de coleópteros?.
EP2658977A4 (en) 2010-12-30 2015-03-18 Dow Agrosciences Llc NUCLEIC ACID MOLECULES TARGETING VACUUOUS ATPASE SUBUNIT C AND CONFERRING RESISTANCE TO HARMFUL CEREOPTERES
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
AU2012300401B2 (en) 2011-08-26 2018-02-08 Ginkgo Bioworks, Inc. Compositions and methods for high fidelity assembly of nucleic acids
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2841601B1 (en) 2012-04-24 2019-03-06 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
ES2683707T3 (es) 2012-05-02 2018-09-27 Ibis Biosciences, Inc. Secuenciación de ADN
WO2013166304A1 (en) 2012-05-02 2013-11-07 Ibis Biosciences, Inc. Dna sequencing
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP2015518713A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Ｕｔｒｎ発現を調節するための組成物及び方法
JP2015518712A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Ｍｅｃｐ２発現を調節するための組成物及び方法
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
WO2013173638A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
EP2850086B1 (en) 2012-05-18 2023-07-05 Pacific Biosciences Of California, Inc. Heteroarylcyanine dyes
US20150191719A1 (en) 2012-06-25 2015-07-09 Gen9, Inc. Methods for Nucleic Acid Assembly and High Throughput Sequencing
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
KR102237882B1 (ko) 2012-08-15 2021-04-07 아이오니스 파마수티컬즈, 인코포레이티드 변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
CA2880869A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US20160046997A1 (en) 2012-10-18 2016-02-18 Oslo Universitetssykehus Hf Biomarkers for cervical cancer
DK2909339T3 (en) 2012-10-18 2018-08-13 Idexx Lab Inc Kits comprehensive controls for nucleic acid amplification
EP2951191B1 (en) 2013-01-31 2018-10-17 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
EP3828277B1 (en) 2013-03-13 2023-06-07 Gen9, Inc. Compositions, methods and apparatus for oligonucleotides synthesis
KR102482890B1 (ko) 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
EP3033422A4 (en) 2013-08-16 2017-08-02 Rana Therapeutics Inc. Oligonucleotides targeting euchromatin regions of genes
CN105682687A (zh) * 2013-08-16 2016-06-15 Rana医疗有限公司 异染色质形成性非编码rna
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en) 2013-10-21 2015-04-30 Isis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
BR112016010165A2 (pt) 2013-11-21 2017-12-05 Somalogic Inc composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas
EP3082469B1 (en) 2013-12-20 2023-09-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests
BR102014031844A2 (pt) 2013-12-20 2015-10-06 Dow Agrosciences Llc ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
WO2015142910A1 (en) 2014-03-17 2015-09-24 Isis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143246A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
JP2017514492A (ja) 2014-05-07 2017-06-08 ダウ アグロサイエンシィズ エルエルシー 鞘翅目害虫に対する抵抗性を付与するｄｒｅ４核酸分子
US10093967B2 (en) 2014-08-12 2018-10-09 The Regents Of The University Of Michigan Detection of nucleic acids
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
EP3037432B1 (en) 2014-12-22 2020-06-17 Dow AgroSciences LLC Nucampholin nucleic acid molecules to control coleopteran insect pests
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
EP3262181B1 (en) 2015-02-23 2024-04-10 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US20160264991A1 (en) 2015-03-13 2016-09-15 Dow Agrosciences Llc Rna polymerase i1 nucleic acid molecules to control insect pests
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
BR102016012010A2 (pt) 2015-05-29 2020-03-24 Dow Agrosciences Llc Molécula de ácido nucleico, de ácido ribonucleico (rna) e de ácido ribonucleico de filamento duplo (dsrna), usos de célula, planta e semente, produto primário, bem como métodos para controlar uma população de pragas coleópteras e/ou hemípteras, para melhorar o rendimento de uma cultura, e para produzir uma célula vegetal transgênica e uma planta transgênica
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US10533175B2 (en) 2015-09-25 2020-01-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Ataxin 3 expression
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
EP3397288A4 (en) 2015-12-31 2019-09-11 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING ATAXIN-2 EXPRESSION
EP3400300A4 (en) 2016-01-05 2019-08-07 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING LRRK2 EXPRESSION
US10577607B2 (en) 2016-03-16 2020-03-03 Ionis Pharmaceuticals, Inc. Modulation of DYRK1B expression
EP3429690A4 (en) 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHOD FOR MODULATING KEAP1
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
KR20190058477A (ko) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 폴리뉴클레오티드 구축물
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
CN109661233A (zh) 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
EP3538657A4 (en) 2016-11-10 2021-02-17 Dow AgroSciences LLC CYTOCHROME B (CYTB) NUCLEIC ACID MOLECULES FOR THE CONTROL OF PATHOGENS
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
EP3342780A1 (en) 2016-12-30 2018-07-04 Dow AgroSciences LLC Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
CA3055565A1 (en) 2017-03-08 2018-09-13 The Regents Of The University Of Michigan Analyte detection
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
AU2019206731A1 (en) 2018-01-15 2020-07-30 Ionis Pharmaceuticals, Inc. Modulators of DNM2 expression
TWI840345B (zh) 2018-03-02 2024-05-01 美商Ionis製藥公司 Irf4表現之調節劑
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
US11365416B2 (en) 2018-04-11 2022-06-21 Ionis Pharmaceuticals, Inc. Modulators of EZH2 expression
MX2020009416A (es) 2018-04-13 2021-01-08 Bristol Myers Squibb Co Nuevos reactivos a base de fosforo (v), procesos para su preparacion y su uso en la elaboracion de compuestos de organofosforo (v) estereo-definidos.
WO2019217708A1 (en) 2018-05-09 2019-11-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
US20210355497A1 (en) 2018-05-09 2021-11-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fxi expression
WO2019241648A1 (en) 2018-06-14 2019-12-19 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing stmn2 expression
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
MX2021000922A (es) 2018-07-25 2021-03-31 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de la atxn2.
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
WO2020102630A1 (en) 2018-11-15 2020-05-22 Ionis Pharmaceuticals, Inc. Modulators of irf5 expression
MY205095A (en) 2018-11-21 2024-10-01 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
US11214803B2 (en) 2019-01-31 2022-01-04 Ionis Pharmaceuticals, Inc. Modulators of YAP1 expression
KR20210134686A (ko) 2019-02-27 2021-11-10 아이오니스 파마수티컬즈, 인코포레이티드 Malat1 발현의 조절인자
CN117431244A (zh) 2019-03-29 2024-01-23 Ionis制药公司 用于调节ube3a-ats的化合物和方法
EP4660307A2 (en) 2019-07-26 2025-12-10 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
WO2021030778A1 (en) 2019-08-15 2021-02-18 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds and uses thereof
CN111039977B (zh) * 2019-12-31 2022-11-08 广州同隽医药科技有限公司 一种亚磷酰化试剂及其在寡核苷酸合成中的应用
AR121446A1 (es) 2020-02-28 2022-06-08 Ionis Pharmaceuticals Inc Compuestos y métodos para modular smn2
JP7738573B2 (ja) 2020-05-01 2025-09-12 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ａｔｘｎ１を調節するための化合物及び方法
CN116096899A (zh) 2020-06-29 2023-05-09 Ionis制药公司 调节plp1的化合物和方法
UY39344A (es) 2020-07-28 2022-02-25 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de app
CA3186935A1 (en) 2020-08-07 2022-02-10 Paymaan JAFAR-NEJAD Compounds and methods for modulating scn2a
TW202227101A (zh) 2020-11-18 2022-07-16 美商Ionis製藥公司 用於調節血管收縮素原表現之化合物及方法
TW202242111A (zh) 2020-12-18 2022-11-01 美商Ionis製藥公司 用於調節因子ｘｉｉ之化合物及方法
CN117480008A (zh) 2021-05-31 2024-01-30 金斯瑞美国有限公司 用于dna合成的电接枝膜
MX2023015230A (es) 2021-06-18 2024-01-18 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de ifnar1.
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
KR20250075637A (ko) 2022-09-23 2025-05-28 아이오니스 파마수티컬즈, 인코포레이티드 Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
US12168674B1 (en) 2023-12-08 2024-12-17 Oligo Foundry, Inc. Reagents and methods for the highly-efficient synthesis and purification of biopolymers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035719A2 (en) 1980-02-29 1981-09-16 University Patents, Inc. Process for producing modified inorganic polymers, their use in producing polynucleotides, and a reagent useful in these processes
EP0040099A1 (en) * 1980-05-14 1981-11-18 ens BIO LOGICALS INC. Polynucleotide synthesis
EP0061746A1 (en) 1981-03-27 1982-10-06 University Patents, Inc. Phosphoramidite compounds and their use in producing oligonucleotides
EP0090789A1 (en) * 1982-03-26 1983-10-05 Monsanto Company Chemical DNA synthesis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310662A (en) * 1979-12-26 1982-01-12 Genentech, Inc. Nucleosidic phosphorylating agent and methods
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
NL8102323A (nl) * 1981-05-12 1982-12-01 Unilever Nv Fosforzuurderivaten, werkwijze ter bereiding daarvan, alsmede werkwijze voor het fosforyleren van organische hydroxylverbindingen en fosfortriesterintermediairen voor gebruik in de synthese van desoxy- en ribo-nucleinezuren (dna en rna).
US4419509A (en) * 1981-08-24 1983-12-06 Eli Lilly And Company Process for de-cyanoethylating blocked nucleotides
US4476301A (en) * 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4605735A (en) * 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
NL8302353A (nl) * 1983-07-01 1985-02-01 Stichting Katholieke Univ Fosforyleringsmiddel; werkwijze voor het bereiden daarvan; werkwijze voor het fosforyleren van een organische hydroxyl- of amineverbinding.
US4591614A (en) * 1983-10-07 1986-05-27 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035719A2 (en) 1980-02-29 1981-09-16 University Patents, Inc. Process for producing modified inorganic polymers, their use in producing polynucleotides, and a reagent useful in these processes
EP0040099A1 (en) * 1980-05-14 1981-11-18 ens BIO LOGICALS INC. Polynucleotide synthesis
EP0061746A1 (en) 1981-03-27 1982-10-06 University Patents, Inc. Phosphoramidite compounds and their use in producing oligonucleotides
EP0090789A1 (en) * 1982-03-26 1983-10-05 Monsanto Company Chemical DNA synthesis

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAN. J. CHEM., vol. 58, 1980, pages 2686
Chemical Reviews, Vol. 77, No. 2, April 1977, V. AMARNATH et al.: 'Chemical Synthesis of Oligonucleotides' pages 183-217, see pages 194-195 *
H. KÖSTER, TETRAHEDRON LETTERS, 1972, pages 1527 - 1530
HINBLICK, CAN. J.CHEM, vol. 58, 1980, pages 2686
Journal of the American Chemical Society, Vol. 98, No. 12, 09 June 1976, R.L. LETSINGER et al. 'Synthesis of Thymidine Oligonucleotides by Phosphite Triester Intermediates' pages 3655-3661, see page 3656, Schema 1, page 3657; 2,2,2-Trichloroethyl Phosphotriesers - page 3658; cited in the application *
LIEBIGS ANN. CHEM., 1978, pages 982
NUCLEIC ACIDS RES, vol. 6, 1979, pages 2096
TETRAHEDRON LETT., vol. 24, 1983, pages 747
Tetrahedron Letters, Vol. 22, No. 20, 1981, S.L. BEAUCAGE et al.: 'Deoxynucleoside Phosphoramidites - A New Class of Key Intermediates for Deoxypolynucleotide Synthesis:' pages 1859-1862, see page 1859 *
VON W.B. LUNSFORD, J. AMER.CHEM.SOC, vol. 98, no. 12, pages 3655 - 3661

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216357A3 (en) * 1985-09-25 1988-08-31 Nippon Zeon Co., Ltd. Phosphoramidite compounds and process for production thereof
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US9034798B2 (en) 2003-01-16 2015-05-19 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Also Published As

Publication number Publication date
DE3474964D1 (en) 1988-12-08
IT1198910B (it) 1988-12-21
AU3313784A (en) 1985-03-12
ATE38386T1 (de) 1988-11-15
JPS6250479B2 (enExample) 1987-10-24
JPH0411555B2 (enExample) 1992-02-28
IT8409482A0 (it) 1984-08-17
EP0152459B1 (de) 1988-11-02
EP0152459A1 (de) 1985-08-28
CA1234060A (en) 1988-03-15
DE3329892A1 (de) 1985-03-07
JPH01301691A (ja) 1989-12-05
US4725677A (en) 1988-02-16
JPS60502102A (ja) 1985-12-05

Similar Documents

Publication Publication Date Title
EP0152459B1 (de) Verfahren zur herstellung von oligonucleotiden
USRE34069E (en) Process for the preparation of oligonucleotides
EP0399330B1 (de) Modifiziertes Phosphoramidit-Verfahren zur Herstellung von modifizierten Nukleinsäuren
DE69404289T2 (de) Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
DE69227793T2 (de) Verfahren und Verbindungen für die Festphase-Synthese von Oligonukleotiden und Analogen
DE69725866T2 (de) Festphasen-synthese
DE69125380T2 (de) Durch reduktion orthogonal entfernbare hydroxylschutzgruppen und ihre verwendung in der chemischen synthese von oligonukleotiden
DE69829760T2 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
EP0707591B1 (de) Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung
DE69724218T2 (de) Universale feste träger und verfahren zu ihrer verwendung
DE60209128T2 (de) Aktivatoren für die oligonukleotidsynthese
EP0818460B1 (de) Festphasensynthese von Oligonucleotiden
DE60103145T2 (de) Verfahren zur herstellung von phoshphorothioate triestere
DE60109047T2 (de) Synthone zur herstellung von oligonukleotiden
DE4213703A1 (de) Fluoreszenzmarkierte Verbindungen, ihre Herstellung und Verwendung
DE69824843T2 (de) Verfahren zur herstellung von modifizierten p-chiralen nucleotid-analoga
DE69401136T2 (de) Modifizierte Oligodeoxyribonukleotide, ihre Herstellung und ihre therapeutische Verwendung
DE2848054A1 (de) Verfahren zur herstellung von polynucleotiden mit bestimmter sequenz
EP0124561B1 (de) Verfahren zur herstellung von oligonucleosidphosphonaten
DE3881691T2 (de) Polydeoxyribonukleotide, pharmazeutische zusammensetzungen, verwendung und herstellung von polydeoxyribonukleotiden.
EP0644196B1 (de) TTTr als Schutzgruppe in der Nukleotidsynthese
EP0649855A1 (de) Verwendung von mit enzymatisch abspaltbaren Schutzgruppen versehenen Nukleosiden und Nukleosid-Derivaten in der Synthese von Oligonukleotiden
DE3928900A1 (de) Neue nucleotidderivate, ihre herstellung und ihre verwendung
DE69613971T2 (de) Oligonukelotide mit transversalkovalenter bindung, verfahren zu ihrer herstellung und darin benutztes synthon
DE10041539A1 (de) Neue Amiditderivate zur Synthese von Polymeren auf Oberflächen

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK JP US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1984903173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1984903173

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1984903173

Country of ref document: EP